Excellent Results .
Q3FY24 Financial Highlights
Operating revenue was Rs. 586.1 cr., up by 22.2% YoY driven by market share gains, new launches, the addition of new customers, an increase in our share with existing customers, and incremental contributions from the acquired Teva facility.
Gross profit was Rs. 313.3 cr., up by +30.4% YoY with a Gross margin of 53.5%.
EBITDA was Rs. 133 cr., grew by 73.6% with an EBITDA margin of 22.7%
EPS grew by 17.8% YoY to Rs. 1.84
Business Highlights
US Market
US & North America Formulation business reported growth of 15.8% YoY to Rs. 673.1 cr.in 9MFY24 on account of new product launches and also due to an increase in the share of existing products.
UK and Europe Market
Revenue of Rs. 710.2 cr. from the UK and Europe Formulation business in 9MFY24 as compared to Rs. 561.3 cr. during last year, registering a growth of 26.5%.
Australia and New Zealand Market
Australia and New Zealand business reported Rs. 155.5 cr. in 9MFY24, which grew by 6.4% YoY, due to incremental market share.
RoW Market
RoW business reported Rs. 78.5 cr. in 9MFY24
Other Highlights
In 9MFY24, the capex incurred was Rs 160.6 cr. Capex investment is in line with plan for scaling the acquired manufacturing unit from Teva Pharma in Goa which will drive future growth.
Cash Balance at the end of 31st December 2023 is at Rs 688 cr.
In 9MFY24, Cash from Operations is at Rs 169.0 cr. and Free Cash Flow is at 8.4 cr.
4ef86101-8fef-4acb-8b5e-bb5b96d4ef63.pdf (bseindia.com)
| Subscribe To Our Free Newsletter |
